



**FOR IMMEDIATE RELEASE**

**CORE LAB ANNOUNCES THE RESULTS OF ITS 2018 ANNUAL SHAREHOLDER MEETING**

AMSTERDAM (31 May 2018) – Core Laboratories N.V. (NYSE: "CLB US" and Euronext Amsterdam: "CLB NA") announces it held its annual shareholder meeting on May 24, 2018 in Amsterdam, The Netherlands. At that meeting, the shareholders re-elected Ms. Margaret Ann van Kempen and elected Mr. Lawrence Bruno to the supervisory board. The vote results for all matters voted upon at the annual meeting of shareholders on May 24, 2018 are as follows:

Proposal No. 1 - Election of Class I Directors: The election of each Class III supervisory director was approved as follows:

<u>Nominee</u>	<u>For</u>	<u>Withheld</u>	<u>Broker Non-Votes</u>
Margaret Ann van Kempen	37,897,401	348,072	2,625,157
Lawrence Bruno	37,900,920	344,553	2,625,157

Proposal No. 2 – Appointment of KPMG: The appointment of KPMG as the Company's independent registered public accountants for the fiscal year ending December 31, 2018 was approved as follows:

<u>For</u>	<u>Against</u>	<u>Abstentions</u>	<u>Broker Non-Votes</u>
40,771,013	56,970	42,647	0

Proposal No. 3 - Confirm and Adopt the Dutch Statutory Annual Accounts: The confirmation and adoption of the Company's Dutch Statutory Annual Accounts in the English language for the fiscal year ended December 31, 2017 was approved as follows:

<u>For</u>	<u>Against</u>	<u>Abstentions</u>	<u>Broker Non-Votes</u>
40,743,644	16,134	110,852	0

Proposal No. 4 - Approve and Resolve the Cancellation of Repurchased Shares: The approval of the cancellation of the Company's repurchased shares held by the Company in its name at 12:01 a.m. CEST on May 24, 2018 was approved as follows:

<u>For</u>	<u>Against</u>	<u>Abstentions</u>	<u>Broker Non-Votes</u>
40,689,657	27,019	153,954	0

Proposal No. 5 - Approve Extension - Repurchase up to 10% of Issued Share Capital: The approval of the extension of the existing authority to repurchase up to 10% of the Company's issued share capital until November 24, 2019 was approved as follows:

<u>For</u>	<u>Against</u>	<u>Abstentions</u>	<u>Broker Non-Votes</u>
40,531,421	204,258	134,951	0

Proposal No. 6 - Approve Extension to Issue Shares and/or Grant Rights: The approval of the extension of the authority to issue shares and/or to grant rights (including options to purchase) with respect to the Company's common and preference shares up to a maximum of 10% of outstanding shares per annum until November 24, 2019 was approved as follows:

<u>For</u>	<u>Against</u>	<u>Abstentions</u>	<u>Broker Non-Votes</u>
38,134,053	79,692	31,728	2,625,157

Proposal No. 7 - Approve Extension to Limit or Exclude Preemptive Rights: The approval of the extension of the authority to limit or exclude the preemptive rights of the holders of the Company's common shares and/or preference shares up to a maximum of 10% of outstanding shares per annum until November 24, 2019 was approved as follows:

<u>For</u>	<u>Against</u>	<u>Abstentions</u>	<u>Broker Non-Votes</u>
37,485,153	724,711	35,609	2,625,157

Proposal No. 8A - Approve the Compensation of the Company's Executive Officers: The compensation program regarding the Company's named executive officers was approved as follows:

<u>For</u>	<u>Against</u>	<u>Abstentions</u>	<u>Broker Non-Votes</u>
35,702,436	2,510,251	32,786	2,625,157

Proposal No. 8B - Approve the Frequency of the Vote to Approve Compensation of the Company's Executive Officers: The frequency of the vote regarding the Company's compensation philosophy, policies and procedures should be as follows:

<u>1 Year</u>	<u>2 Years</u>	<u>3 Years</u>	<u>Broker Non-Votes</u>
37,351,361	18,090	257,881	3,243,298

For more information contact:

Chris Hill – CFO, +1 713 328 6401

Gwen Y. Schreffler - VP Corporate Development and Investor Relations, +1 713 328 6210

[investor.relations@corelab.com](mailto:investor.relations@corelab.com)

###